Two-year analysis of efficacy and safety data from Black and Hispanic people with relapsing multiple sclerosis receiving ocrelizumab treatment in the CHIMES trial

Authors
Category Primary study
ConferenceThe 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Year 2024
This article has no abstract
Epistemonikos ID: 48f7aaaa8cba66ce5bd3d26fcd82293dcb3fdf67
First added on: Apr 04, 2026